Cancer Biopsy Market Analysis

Cancer Biopsy Market Analysis

To get key market trends

  Download Free Sample

Based on biopsy type, the cancer biopsy market is segmented into tissue biopsy, liquid biopsy, image-guided biopsy and other biopsy types. The tissue biopsy segment dominates the market and is anticipated to grow at 8.3% CAGR over the forecast period. The tissue biopsy segment is further categorized into needle biopsy, surgical biopsy, and other tissue biopsy types.
 

• The segment's dominance is attributed primarily to its preference as the gold standard for cancer diagnosis, providing highly accurate and reliable results.
   
• Tissue biopsies offer comprehensive histological and molecular information, enabling accurate tumor characterization, which is essential for determining appropriate treatment strategies. The method's reliability in diagnosing various cancers, including breast, lung, and prostate cancers, contributes to its widespread adoption.
   
• Additionally, advancements in minimally invasive techniques and imaging technologies have enhanced the precision and safety of tissue biopsies, further solidifying their dominance.

Based on the products and services, the cancer biopsy market is categorized into products and services The product segment accounted for highest market share of 65.5% in 2023 The product segment further bifurcated into biopsy needle/guns, biopsy forceps, kits and reagents, and consumables.
 

• The dominance of this segment is driven by advancements in biopsy technology, which improve accuracy and patient outcomes. Additionally, the rise in global cancer cases has led to higher demand for these products, as early detection and accurate diagnosis are critical for effective treatment.
   
• Furthermore, the ongoing development and enhancement of biopsy products, backed by extensive research and clinical validation, have significantly increased their adoption in the market. For instance, in 2023, the NCI highlighted that the continuous refinement of biopsy products led to a 20% increase in adoption rates among healthcare providers from 2020 to 2023, driven by the positive impact of new innovations on patient care and diagnostic precision.
   
• These factors collectively drive the growth of the biopsy product segment in the market, underscoring its vital role in the accurate and effective diagnosis of cancer.
   

Based on cancer type, the cancer biopsy market is segmented into breast, colorectal, stomach, lung, liver, prostrate, ovarian, and other cancer types. The breast cancer segment is poised to reach USD 8.7 billion by 2032.
 

• The increasing incidence of breast cancer worldwide has driven the demand for biopsies, making them an essential component of breast cancer management. For instance, according to the NCI, the incidence rate of breast cancer increased by approximately 0.5% per year between 2013 and 2018. In 2023, the estimated number of new breast cancer cases was around 297,790. This rising prevalence underscores the urgent need for continuous advancements in early detection, diagnosis, and treatment strategies, thereby propelling the demand for biopsy procedures.
   
• Additionally, the development of advanced biopsy techniques, supported by robust research and clinical evidence, has further bolstered the demand within this segment.
   
• These factors collectively drive the growth of the breast cancer segment in the market, highlighting its pivotal role in addressing the increasing burden of breast cancer globally.
   

Based on end-user, the cancer biopsy market is segmented into hospitals, cancer research centers, diagnostic centers, and research and academics. The hospital segment dominated the market accounting for USD 10.4 billion in 2023.
 

• Hospitals' dominance is due to their extensive diagnostic capabilities and access to cutting-edge medical technologies. Equipped with advanced imaging and biopsy tools, they facilitate accurate and efficient cancer diagnosis.
   
• Their ability to perform complex biopsies, such as image-guided and surgical biopsies, within a hospital setting enhances patient trust and drives the preference for hospitals over other healthcare providers.
   
• Additionally, hospitals often serve as primary care centers for cancer patients, further solidifying their leading position in the market.
   

U.S. cancer biopsy market size accounted for USD 8.9 billion in 2023 and is anticipated to reach USD 18 billion by 2032.
 

• The U.S. prominence in the North American market is due to advanced healthcare infrastructure, significant investment in research and development, and the presence of leading medical device companies.
   
• The country’s robust focus on early cancer detection and personalized medicine, coupled with widespread adoption of innovative biopsy technologies, contributes to its dominance.
   
• Additionally, strong governmental support, a high incidence of cancer, and extensive clinical trials further enhance the U.S.'s leadership in the region, making it a key player in the North American market.
   
• For instance, according to the American Cancer Society, approximately 1.9 million new cancer cases are expected in 2024, highlighting the increasing need for advanced diagnostic tools. Thus, the growing demand for innovative diagnostic tools and techniques continues to solidify the U.S.'s leadership in the region.
   

The Asia Pacific cancer biopsy market is poised for rapid growth with a CAGR of 8.7% during the forecast period.
 

• The growing awareness and utilization of genetic testing in the Asia Pacific region emphasize the crucial need for early and accurate cancer detection. This trend has increased the demand for advanced biopsy techniques providing precise diagnoses and effective treatment strategies.
   
• Furthermore, the advancement and enhanced accessibility of innovative biopsy technologies in the region, supported by government initiatives and healthcare investments, have significantly contributed to market growth.